Share on StockTwits

Sucampo Pharmaceuticals (NASDAQ:SCMP) major shareholder S&R Technology Holdings, Llc sold 15,000 shares of the company’s stock on the open market in a transaction dated Friday, July 18th. The shares were sold at an average price of $6.27, for a total transaction of $94,050.00. Following the completion of the sale, the insider now directly owns 22,805,802 shares of the company’s stock, valued at approximately $142,992,379. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 0.96% on Monday, hitting $6.18. 57,828 shares of the company’s stock traded hands. Sucampo Pharmaceuticals has a one year low of $5.40 and a one year high of $11.00. The stock’s 50-day moving average is $7.04 and its 200-day moving average is $7.69. The company has a market cap of $269.2 million and a price-to-earnings ratio of 25.68.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.02 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.04 by $0.02. The company had revenue of $22.20 million for the quarter, compared to the consensus estimate of $24.19 million. The company’s quarterly revenue was up 31.4% on a year-over-year basis. On average, analysts predict that Sucampo Pharmaceuticals will post $0.13 earnings per share for the current fiscal year.

A number of research firms have recently commented on SCMP. Analysts at MLV & Co
cut their price target on shares of Sucampo Pharmaceuticals from $14.00 to $11.00 in a research note on Friday, May 9th. They now have a “buy” rating on the stock. Analysts at Zacks downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st.

Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.